| Author/Editor | Šebeštjen, Miran; Žegura, Branka; Videčnik, Viktor; Keber, Irena | |
| Title | Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia | |
| Type | članek | |
| Source | Coron Artery Dis | |
| Vol. and No. | Letnik 16, št. 3 | |
| Publication year | 2005 | |
| Volume | str. 175-80 | |
| Language | eng | |
| Abstract | Background Early functional and morphological changes in the course of the atherosclerotic process are manifested as endothelial dysfunction and increased intima-media Ihickness (IMT) of the arterial wall. These are both associated with various atherosclerotic risk factors. We investigated whether the same factors are associated with functional and morphological changes of the arterial wall in men with combined hyperlipidemia. Methods Flow-mediated dilatation (FMD) of the brachial artery and carotid IMT were measured in 72 male patients aged 46±5 years with combined hyperlipidemia. Serum lipoproteins, fibrinolytic and coagulation parameters, blood glucose, proinflammatory cytokines and C-reactive protein were also measured. Results Tumor necrosis factor-alpha, interleukin 6 and apolipoprotein (apo) B were found to be independent predictors of FMD, explaining 87% of FMD variability in multivariate analysis. On the other hand, total tissue factor pathway inhibitor and apo B were independent predictors ofincreased carotid IMT, explaining 82% of the variation in carotid IMT. Conclusions Apo B, which is a marker for the pre. the atherogenic lipoproteins, is associated with bc functional and morphological changes of the artery, addition, in asymptomatic overweight middle-agec with combined hyperlipidemia, functional changes are associated with proinflammatory cytokines, wh morphological changes are associated with coagu parameters. | |
| Descriptors | ATHEROSCLEROSIS HYPERLIPIDEMIA CAROTID ARTERIES BRACHIAL ARTERY TUNICA INTIMA MIDDLE AGE TUNICA MEDIA BLOOD PRESSURE BODY MASS INDEX BLOOD GLUCOSE C-REACTIVE PROTEIN INTERLEUKIN-6 LIPOPROTEIN(A) LIPOPROTEINS TUMOR NECROSIS FACTOR PLASMINOGEN ACTIVATOR INHIBITOR 1 ALTEPLASE |